KPTI NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Karyopharm Therapeutics Inc · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 7.41 USD
-22.1% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is -10.0% below the Trend Line and sits at 51.2% of its 52-week range. The latest completed week returned -22.1%, after a -27.4% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is mixed with 38/100 conviction, while the latest news-sentiment score is 53/100. Near-term considerations: earnings are due in 12d.

Setup score 45 out of 100
Latest Close 7.41 USD 24 Jul 2026
1W Return -22.1% latest completed week
4W Return -27.4% short-term follow-through
12W Return -15.5% quarterly tape
Trend Breadth 82.7% 43 of 52 weeks active
Volume Ratio 2.3x vs 13-week average
What is working
  • The trend backdrop is active with a 16-week active streak.
  • Activity pressure is positive on the latest completed week.
  • Volume is elevated versus the 13-week average, confirming attention.
  • Activity pressure is constructive, supporting the smart-money activity read.
What could go wrong
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Next-week expectancy is negative at 42.09% based on similar historical setup states.
  • The share remains more than 20% below its 52-week high.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -22.1% Latest completed week; four-week move -27.4%. Indicator stack 90/59 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 42.09% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Mixed 38/100 conviction; expected move 66.5%. News sentiment 53/100 69 relevant articles in the latest sentiment read. Event risk 12d Next report is scheduled for 10 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is -10.0% below the Trend Line and sits at 51.2% of its 52-week range. The latest completed week returned -22.1%, after a -27.4% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 2.3x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.8212-week average 0.65

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure9/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership11/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.82Current proprietary activity-pressure read.
Buy signals1Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -27.4% over four weeks, -15.5% over 12 weeks, and 70.3% over one year. The current trend has remained active for 16 consecutive weeks.

Performance by holding period

1W-22.1%
4W-27.4%
12W-15.5%
26W12.4%
52W70.3%
Active trend streak16 weeks
Active weeks in one year43
Trend breadth82.7%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.55Latest activity-pressure read.
Pressure change-6.2%Four-week change in activity pressure.
Leadership-5.88Latest relative-leadership reading.
RS change-119.4%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 73% Model confidence 70%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength54/100Blend of value, momentum, and quality. Underlying universe rank 47; rank 1 is best.
Value51/100Relative valuation strength. Underlying universe rank 50; rank 1 is best.
Quality50/100Profitability and accounting quality. Underlying universe rank 51; rank 1 is best.
Momentum51/100Medium-term price momentum. Underlying universe rank 50; rank 1 is best.
Growth51/100Revenue and earnings growth. Underlying universe rank 50; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
1.1x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-19.2%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
96.0%
Gross profit retained from each unit of revenue.
Operating margin
-98.0%
Operating profit retained from revenue.
Free-cash-flow margin
-39.1%
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
6.3%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-5.2%
Net share repurchases relative to market value.
Shareholder yield
-5.2%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-0.9x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningMixed

KPTI shows mixed options pressure with a 38/100 conviction score, put-call volume ratio of 1.55, expected move of 66.5%, and Sharemaestro trend signal active.

Conviction38/100
Expected move66.5%
Put/call volume1.55
Pressure-13
Speculation1
Volatility96
Trend agreement86
Open options detail
Insider activity12 / 7

12 acquisitions and 7 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment53/100

Weighted news tone is neutral across 69 relevant articles.

16 positive · 48 neutral · 5 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings12dNext report is scheduled for 10 Aug 2026; event risk rises as the date approaches.
Options expected move66.5%Nearest-chain priced movement where available.
52-week drawdown-32.6%Distance below the 52-week high.
13-week volatility9.5%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher12 of 2614 weeks finished lower.
Best week+37.1%Week of 13 Feb.
Worst week-28.2%Week of 27 Mar.
Latest week-22.1%Week of 24 Jul.

Shape of recent returns

Strong gains10
Modest gains2
Flat weeks0
Modest losses6
Sharp losses8
Recent vol9.5%13-week weekly-return volatility.
Base vol14.4%52-week weekly-return volatility.
Up/down split26/26Count of positive and negative weeks in the 52-week window.
Average skew12.3% / -8.3%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape53/100

Trend, activity pressure, participation, and risk combine to a 53/100 tape read.

 Indicator analysis82/100

Latest 12-week confirmation: trend 12/12, activity pressure 9/12, relative leadership 11/12.

Activity pressure 0.82; No reversal markers Next-Week ExpectancyNegative 42.09%

Next-week expectancy is negative with a 42.09% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors51/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 83; Small Cap Core rank 53 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options57/100

KPTI shows mixed options pressure with a 38/100 conviction score, put-call volume ratio of 1.55, expected move of 66.5%, and Sharemaestro trend signal active.

Mixed · Options-market disagreement · Expected move 66.5% Sentiment53/100

Weighted news tone is neutral across 69 relevant articles.

Karyopharm Therapeutics Inc (KPTI) Shareholder Structure: Major Shareholders & Institutional Holdings Insiders12 / 7

12 acquisitions and 7 disposals in the latest 180-day insider tape.

 Earnings12d

Next report is scheduled for 10 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 20267.41 USD-22.1%8.24 USD10.86 USD0.55-5.885.6MOn
17 Jul 20269.51 USD-8.0%8.24 USD10.99 USD0.9919.491.7MOn
10 Jul 202610.34 USD7.7%8.15 USD11.08 USD0.9925.951.9MOn
3 Jul 20269.60 USD-6.0%8.04 USD11.17 USD0.8320.281.7MOn
26 Jun 202610.21 USD13.2%7.91 USD11.26 USD0.5930.275.1MOn
19 Jun 20269.02 USD-5.1%7.76 USD11.37 USD0.2611.141.3MOn
12 Jun 20269.50 USD4.6%7.65 USD11.50 USD0.0221.001.6MOn
5 Jun 20269.08 USD-0.2%7.53 USD11.63 USD-0.1619.331.9MOn
29 May 20269.10 USD11.5%7.40 USD11.79 USD-0.1515.111.7MOn
22 May 20268.16 USD6.4%7.29 USD11.95 USD-0.087.012.5MOn
15 May 20267.67 USD-11.2%7.23 USD12.12 USD0.062.243.7MOn
8 May 20268.64 USD-1.5%7.17 USD12.30 USD0.0714.921.2MOn
1 May 20268.77 USD1.3%7.06 USD12.49 USD-0.0223.021.5MOn
24 Apr 20268.66 USD0.6%6.98 USD12.69 USD-0.3222.882.4MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.